Eli Lilly and Company / Adocia SA

Type 1 and Type 2 Diabetes Mellitus

Disease Overview

Type 1 diabetes is an autoimmune destruction of pancreatic beta cells requiring lifelong insulin replacement; Type 2 is a progressive metabolic disorder of insulin resistance and beta-cell decline, with insulin needed in advanced disease. Mealtime (prandial) insulins blunt postprandial glucose excursions, but standard rapid-acting analogs lag physiologic insulin secretion, leaving residual glycemic variability and hypoglycemia risk.

Competitive Landscape

The prandial insulin market in 2014 was a Lilly–Novo Nordisk–Sanofi oligopoly: Lilly's Humalog (insulin lispro), Novo's NovoLog/NovoRapid (aspart), and Sanofi's Apidra (glulisine), all rapid-acting analogs but slower than physiologic insulin. The next competitive frontier was 'ultra-rapid' analogs designed to better mimic first-phase insulin release. Novo Nordisk's Fiasp (faster aspart) was approaching late-stage trials and ultimately approved in 2017, and Lilly was internally developing LY900014/Lyumjev. Adocia's BioChaperone Lispro used a polysaccharide excipient platform to accelerate lispro absorption, demonstrating superior PK/PD vs Humalog across six clinical studies. The $570M Lilly–Adocia alliance gave Lilly an external hedge alongside its internal program, then was terminated in January 2017 — widely interpreted as Lilly choosing its in-house LY900014. Years of arbitration ended largely in Lilly's favor in 2019, with Adocia's $1.8B claim reduced to $11.6M.